working with a data integrator to support swiss pharma clients on CTs; DLT to speed things up a bit
Willy (??)
Leah Houston
Bernard
Catherine
Robert's presentation
scale: billions of transactions in a 3-hour overnight crunch period
trial generating valuable material and guidance for industry governance processes
interaction of technical, operations, and compliance/governance groups
API and Schemata —> starting point for standardization
"This is an industry that runs on standards"
GS1 for txn info and ids,
Everyone obvi wants to look with the W3C standards
all the examples in the spec are very consumer-based; bias and mental model
"Challenges"
Challenge #1: Scale
Standards and misfit b/w W3C as-is today and these use-cases
Challenge #2: Retention req (6 year record-keeping obligation) —> binding VCs and VPs need to be archival/auditable for 6 years!
VP ephemerality (in VC spec)
Lesson#1 Identifier ←→ Company name binding needs to be durable/archival
Challenge #3: How does Company B know that A was handling credentials properly and according to industry and/or regulatory rules, if they just get a log or a recipt?
Logging of credential exchanges? reusing credentials falsely, replay attacks, etc?
Out of scope for now, but we're starting to look at the possibility of a third-party compliance auditor or guarantor? Do they attach additional VCs?
security risks
drug cartel made 25 shell corps to hide infiltration in a drug supply chain
mitigations of legal identity issues
drug cartels have a big R&D budgets for impersonation, counterfeiting, etc— way more tech savvy than many supply chain actors such as smalltown pharmacies!
Q&A
Najid: FMD (I used to work for Pfizer so I know the DCSCA and serialization!); what are your thoughts on B2B2P and P identity?
Orphan disease area? Teaching hospital ... Therapies and vectors?
Volume and complex stakeholders...
Standards around labeling (tagging blood in loop); 200K-1.3m$ therapies! the liabilities (and stakes) are massive there
How do we get everybody on board? Some people are incentivized for intransparency
Bob: One of the pilots in the FDA program was a very expensive personalized drug: the roundtrip; temp control in transit; temperature indicator behind a bar code, so that bar code changed
Georg: Novartis is looking into this for Kamriah; validated (manual) process for now